BAFF CAR-T cells for hard-to-treat autoimmune diseases
Part of Bones, joints & muscles, Brain & nervous system, Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new type of cell therapy called BAFF CAR-T cells (LMY-922) for people with autoimmune diseases that haven't improved with standard treatments. The therapy aims to reset the immune system by targeting and depleting certain immune cells that cause the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 16 and 75 years old.
- You have one of these autoimmune diseases: rheumatoid arthritis, lupus, dermatomyositis, or systemic sclerosis.
- Your disease has not responded well to at least 2 standard treatments (like methotrexate, biologics, or other immune-suppressing drugs).
- Your organs (kidneys, liver, heart, lungs) need to be functioning well enough, and you must not have certain infections, cancers, or other serious health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy called BAFF CAR-T cells (LMY-920) for lupus that hasn't gotten better with standard treatments. It aims to see if these special immune cells can help calm the overactive immune system in lupus.
This trial tests a new CAR-T cell therapy (LMY-922) that targets BAFF in people with certain blood cancers that have not responded to standard treatments. The goal is to see if it can shrink or control the cancer.
This trial tests a new treatment called BAFF CAR-T cells (LMY-920) for people with certain types of lymphoma or multiple myeloma that have come back or not responded to previous treatments. The therapy uses your own immune cells, modified to attack cancer cells, and may offer a new option when standard treatments have not worked.
This trial tests a new CAR-T cell therapy that targets two immune proteins (CD19 and BAFF) to treat autoimmune diseases like lupus or scleroderma. It is for people who have not improved with standard treatments.
This study tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune diseases like rheumatoid arthritis, lupus, dermatomyositis, and scleroderma that haven't responded well to standard treatments. The therapy works by modifying your own immune cells to target and eliminate the B cells that are causing your autoimmune disease.
This trial tests a new treatment using your own immune cells (CAR T-cells) targeting a protein called CD19 to control severe autoimmune diseases like lupus, Sjogren's, scleroderma, dermatomyositis, or vasculitis. The goal is to see if it's safe and can improve symptoms when other treatments haven't worked.
Hear when a new Dermatomyositis (DM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.